Incremental increase in VEGFR1 + hematopoietic progenitor cells and VEGFR2 + endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 235-242

  Jain, Sarika ^a   Ward, Maureen M ^a   O'Loughlin, Jennifer ^a   Boeck, Marissa ^a   Wiener, Naomi ^a   Chuang, Ellen ^a   Cigler, Tessa ^a   Moore, Anne ^a   Donovan, Diana ^a   Lam, Christina ^a   Cobham, Marta V ^a   Schneider, Sarah ^a   Christos, Paul ^a   Baergen, Rebecca N ^a   Swistel, Alexander ^a   Lane, Maureen E ^a   Mittal, Vivek ^a   Rafii, Shahin ^a   Vahdat, Linda T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiogenic switch; Breast cancer; Metastasis; VEGFR1 +; VEGFR2 +

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; GEMCITABINE; IXABEPILONE; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CELL LEVEL; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECURRENT CANCER; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL COUNT; COHORT STUDIES; FEMALE; HEMANGIOBLASTS; HEMATOPOIETIC STEM CELLS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PYRIMIDINES; QUINAZOLINES; THIAZOLES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84857924372     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1906-3     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Brewster AM, Hortobagyi GN, Broglio KR et al (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100:1179-1183
3. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359:2814-2823
4. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746 (Pubitemid 26329660)
5. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
6. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874 (Pubitemid 32878711)
7. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423 (Pubitemid 36842560)
8. Cheang MC, van de Rijn M, Nielsen TO (2008) Gene expression profiling of breast cancer. Annu Rev Pathol 3:67-97 (Pubitemid 351492437)
9. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312 (Pubitemid 350232263)
10. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
11. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
12. LydenD,Hattori K, Dias S et al (2001) Impaired recruitment of bone marrow derived endothelial and a hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201 (Pubitemid 33063774)
13. Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1- positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438:820-827 (Pubitemid 41753060)
14. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V (2008) Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319:195-198
15. Fujita K, Nakayama M, Nakai Y et al (2009) Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy. Cancer Sci 100:1047-1050
16. + Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 15:4561-4571
17. Gao D, Mittal V (2009) The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med 15:333-343
18. Roodhart JM, Langenberg MH, Daenen LG, Voest EE (2009) Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochim Biophys Acta 1796:41-49
19. Dome B, Timar J, Dobos J et al (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66:7341-7347 (Pubitemid 44197717)
20. Furstenberger G, von Moos R, Lucas R et al (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94:524-531 (Pubitemid 43289756)
21. Massa M, Rosti V, Ramajoli I et al (2005) Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 23:5688-5695
22. Richter-Ehrenstein C, Rentzsch J, Runkel S, Schneider A, Schonfelder G (2007) Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat 106:343-349 (Pubitemid 350029682)
23. Naik RP, Jin D, Chuang E et al (2008) Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 107:133-138 (Pubitemid 350179580)
24. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
25. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845 (Pubitemid 44629895)
26. Mancuso P, Antoniotti P, Quarna J et al (2009) Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15:267-273
27. Shaked Y, Henke E, Roodhart JM et al (2008) Rapid chemotherapy- induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263-273
28. Farace F, Massard C, Borghi E, Bidart JM, Soria JC (2007) Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. Ann Oncol 18:1421-1422 (Pubitemid 47305018)
29. Khan SS, Solomon MA, McCoy JP Jr (2005) Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64:1-8 (Pubitemid 40960406)
30. Bahlmann FH, De Groot K, Spandau JM et al (2004) Erythro-poietin regulates endothelial progenitor cells. Blood 103:921-926 (Pubitemid 38129551)
31. Friedrich EB, Werner C, Walenta K, Bohm M, Scheller B (2009) Role of extracellular signal-regulated kinase for endothelial progenitor cell dysfunction in coronary artery disease. Basic Res Cardiol 104:613-620
32. Goss GD, Arnold A, Shepherd FA et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55
33. Spratlin JL, Cohen RB, Eadens M et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780-787
34. Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y (2010) Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC- 18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 116:1027-1032
35. Jain S, Ward M, Chuang E, Cigler T, Moore A, Donovan D et al (2010) The effect of tetrathiomolybdate (TM) on circulating endothelial progenitor cells in women at moderate to high risk of breast cancer recurrence. Proc Breast Cancer Symp; abstr 297